- Home
- APVO vs AURE Comparison
APVO vs AURE Comparison
Compare APVO & AURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- AURE
- Stock Information
- Founded
- APVO 2016
- AURE 2018
- Country
- APVO United States
- AURE Hong Kong
- Employees
- APVO N/A
- AURE N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- AURE Finance: Consumer Services
- Sector
- APVO Health Care
- AURE Finance
- Exchange
- APVO Nasdaq
- AURE Nasdaq
- Market Cap
- APVO 21.7M
- AURE 19.4M
- IPO Year
- APVO N/A
- AURE N/A
- Fundamental
- Price
- APVO $1.09
- AURE $0.49
- Analyst Decision
- APVO
- AURE
- Analyst Count
- APVO 0
- AURE 0
- Target Price
- APVO N/A
- AURE N/A
- AVG Volume (30 Days)
- APVO 757.7K
- AURE 222.1K
- Earning Date
- APVO 11-06-2025
- AURE 02-13-2026
- Dividend Yield
- APVO N/A
- AURE N/A
- EPS Growth
- APVO N/A
- AURE N/A
- EPS
- APVO N/A
- AURE N/A
- Revenue
- APVO N/A
- AURE $142,570.00
- Revenue This Year
- APVO N/A
- AURE N/A
- Revenue Next Year
- APVO N/A
- AURE N/A
- P/E Ratio
- APVO N/A
- AURE N/A
- Revenue Growth
- APVO N/A
- AURE N/A
- 52 Week Low
- APVO $1.07
- AURE $0.31
- 52 Week High
- APVO $298.00
- AURE $2.70
- Technical
- Relative Strength Index (RSI)
- APVO 27.92
- AURE N/A
- Support Level
- APVO $1.39
- AURE N/A
- Resistance Level
- APVO $1.54
- AURE N/A
- Average True Range (ATR)
- APVO 0.09
- AURE 0.00
- MACD
- APVO -0.03
- AURE 0.00
- Stochastic Oscillator
- APVO 3.06
- AURE 0.00
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.